R. Marega, L. Karmani, L. Flamant, P. G. Nageswaran, V. Valembois, B. Masereel, O. Feron, T. V. Borght, S. Lucas, C. Michiels, B. Gallez, D. Bonifazi,
J. Mater. Chem. 2012, 22, 21305-21312
DOI: 10.1039/c2jm33482h
Abstract
Gold nanoparticles (∼5 nm) coated with plasma-polymerized allylamine were produced through plasma vapor deposition and bioconjugated with a monoclonal antibody targeting the epidermal growth factor receptor. The resulting nanoconjugates displayed an antibody loading of about 1.7 nmol mg−1 and efficiently target epidermal growth factor receptor overexpressing cell lines, as ascertained by ELISA and Western blot assays. The in vitro targeting properties were also confirmed in vivo, where a similar biodistribution profile of what was experienced for the unconjugated antibody was observed. Thanks to the possibility of doping the gold nanoparticles with radionuclides during plasma vapor deposition, the proposed functionalization strategy represents a very suitable platform for the in vivo cancer targeting with nanosized multifunctional particles.
